Annexon (ANNX)
(Delayed Data from NSDQ)
$4.70 USD
+0.11 (2.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.69 -0.01 (-0.21%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ANNX 4.70 +0.11(2.40%)
Will ANNX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANNX
Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
Are Medical Stocks Lagging Annexon (ANNX) This Year?
ANNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
What Makes Annexon (ANNX) a New Buy Stock
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
Other News for ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating on Annexon Biosciences: Promising Pipeline and Strategic Growth Potential
10 Health Care Stocks With Whale Alerts In Today's Session
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), ALX Oncology Holdings (ALXO)
Annexon: Unforced Error Sullies Prospects